Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01830426 · ClinicalTrials.gov registry record
Circulating Tumor Cells in Non-Small Cell Lung Carcinoma
A clinical trial of Primary Lung Cancer, sponsored by Epic Sciences.
- Completed
- Registry status
- 232
- Enrollment target
- 3
- Study locations
NCT01830426: Completed study of Primary Lung Cancer, sponsored by Epic Sciences.
NCT01830426 is a study of Primary Lung Cancer that has completed, run by Epic Sciences. The registered enrollment target is 232 participants. The trial reports 3 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01830426, a study of Primary Lung Cancer, has completed, sponsored by Epic Sciences.
- COMPLETED
- Registry status
- 232 participants
- Enrollment target
- 3
- Study locations
Study Summary
The purpose of this study is to establish the circulating tumor cell (CTC) assay as a surrogate for tissue diagnosis of suspected primary lung cancer. This is done through evaluating clinical and molecular markers to stratify the outcome/survival in patients with thoracic malignancies treated at Yale University/Yale-New Haven Hospital, University of California San Diego/Moores Cancer Center, Billings Clinic Cancer Center.
Primary Outcome
After informed consent of the patients, a single tube of blood will be drawn and processed according to the standard protocol. These blood draws will occur upon patient screening or rather the baseline of their treatment, a 6-12 week follow-up, as well as a 12 month follow-up.Furthermore, a biopsy will be taken between baseline and 6-12 week follow-up which will be used upon results of CTC enumeration to illustrate concordance. Epic Sciences staff is fully blinded to the clinical data of the pat
Conditions Studied
Study Locations (3)
California
- Moores Cancer Center - La Jolla
Connecticut
- Yale University - New Haven
Montana
- Billings Clinic Cancer Center - Billings
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 232 participants |
| Start Date | 2012-11 |
| Est. Completion | 2016-01 |
What the finished NCT01830426 record still lists
NCT01830426 is an observational study that tracks outcomes without assigning an intervention. The registered 232 participants enrollment target is mid-sized for trials with a published cap.
The record links to 1 condition, with Primary Lung Cancer appearing as the primary indexed condition, and to 0 interventions.
NCT01830426 reports a single indexed study location in California, Connecticut, Montana.
Frequently Asked Questions
What is clinical trial NCT01830426 about?
NCT01830426 is a clinical study titled "Circulating Tumor Cells in Non-Small Cell Lung Carcinoma". The purpose of this study is to establish the circulating tumor cell (CTC) assay as a surrogate for tissue diagnosis of suspected primary lung cancer. This is done through evaluating clinical and molecular markers to stratify the outcome/survival in patients with thoracic malignancies treated at Yal...
What is the current status of trial NCT01830426?
This trial is currently completed. The enrollment target is 232 participants. The study started on 2012-11. Estimated completion is 2016-01.
What conditions does trial NCT01830426 study?
This clinical trial studies the following conditions: Primary Lung Cancer.
Who is sponsoring clinical trial NCT01830426?
This trial is sponsored by Epic Sciences, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01830426 being conducted?
This trial has 3 study locations across California, Connecticut, Montana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Primary Lung Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01356290 · 232 participants · Phase 2
Antiangiogenic Therapy for Children With Recurrent Medulloblastoma, Ependymoma, ATRT and Rare CNS Tumors
- NCT04753359 · 232 participants · NA
Mediterranean Diet and Weight Loss: Targeting the Bile Acid/Gut Microbiome Axis to Reduce Colorectal Cancer
- NCT04770870 · 232 participants · NA
Post Approval Study2: Hintermann Series H3 Total Ankle Replacement System
- NCT05948943 · 232 participants · Phase 2
Alpelisib in Pediatric and Adult Patients With Lymphatic Malformations Associated With a PIK3CA Mutation.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia